1. Scrip
  2. >>Focus On Asia

Yuhan Licenses Out Degenerative Disc Therapy To Spine Despite Earlier Trial Failure

 
• By Jung Won Shin

South Korean pharma firm licenses out to US venture Spine Biopharma novel peptide drug for degenerative disc disease YH14618, despite a Phase II failure and trial halt in 2016.

3D spinal cord
YUHAN'S DISC DISEASE CANDIDATE LICENSED TO SPINE • Source: Shutterstock

Yuhan Corp. has licensed out its investigative degenerative disc therapy YH14618 to US-based Spine Biopharma LLC in a deal worth up to $218m plus sales royalties, reviving the compound after the leading South Korean pharma company halted clinical development after failure in a Phase II Korean study in 2016.

Under the new agreement, Spine Biopharma will proceed with development, approval, manufacturing and commercialization of the compound in global markets,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Chinese Biotech VC/PE Fundings Rise But Still Modest

 
• By Dexter Jie Yan

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.